Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells $1,295,628.54 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 29,063 shares of the company’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $44.58, for a total value of $1,295,628.54. Following the transaction, the director directly owned 3,530,702 shares in the company, valued at approximately $157,398,695.16. The trade was a 0.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Orbimed Advisors Llc also recently made the following trade(s):

• On Monday, February 2nd, Orbimed Advisors Llc sold 1,890 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.57, for a total value of $84,237.30.
• On Wednesday, December 24th, Orbimed Advisors Llc sold 33,356 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.55, for a total transaction of $1,486,009.80.
• On Friday, December 19th, Orbimed Advisors Llc sold 875 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.49, for a total value of $38,928.75.
• On Thursday, December 18th, Orbimed Advisors Llc sold 100 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.49, for a total transaction of $4,449.00.
• On Wednesday, December 17th, Orbimed Advisors Llc sold 900 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.50, for a total value of $40,050.00.
• On Wednesday, November 26th, Orbimed Advisors Llc sold 1,600 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total transaction of $71,184.00.
• On Tuesday, November 25th, Orbimed Advisors Llc sold 11,890 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.60, for a total transaction of $530,294.00.
• On Monday, November 24th, Orbimed Advisors Llc sold 94,583 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.54, for a total transaction of $4,212,726.82.

Sionna Therapeutics Trading Up 2.4%

Shares of Sionna Therapeutics stock opened at $36.11 on Friday. The firm has a market cap of $1.61 billion and a PE ratio of -7.41. Sionna Therapeutics, Inc. has a 12 month low of $7.26 and a 12 month high of $45.00. The stock has a 50 day moving average of $41.08 and a 200 day moving average of $32.95.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.06.

Hedge Funds Weigh In On Sionna Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SION. Russell Investments Group Ltd. acquired a new position in shares of Sionna Therapeutics in the third quarter valued at about $30,000. BNP Paribas Financial Markets purchased a new stake in Sionna Therapeutics in the second quarter valued at $31,000. GF Fund Management CO. LTD. purchased a new stake in shares of Sionna Therapeutics in the fourth quarter worth about $36,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Sionna Therapeutics during the 2nd quarter worth approximately $45,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Sionna Therapeutics during the fourth quarter valued at $89,000.

Analysts Set New Price Targets

SION has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday, December 29th. Wall Street Zen raised shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Royal Bank Of Canada restated an “underperform” rating and issued a $24.00 price objective on shares of Sionna Therapeutics in a report on Monday, December 1st. BTIG Research reissued a “buy” rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a research note on Wednesday, January 14th. Finally, Lifesci Capital assumed coverage on shares of Sionna Therapeutics in a report on Tuesday, December 23rd. They issued an “outperform” rating and a $60.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $45.43.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.